Clinical Research Directory
Browse clinical research sites, groups, and studies.
Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors
Sponsor: University of Michigan Rogel Cancer Center
Summary
The goal of this exploratory study is to test whether \[18F\]3F-PHPG can be used reliably to map the locations of tumors in patients with neuroendocrine tumors. If so, the results of this study will be used to support further development of \[18F\]3F-PHPG as a clinical tool for neuroendocrine tumor localization and staging.
Official title: An Exploratory Study of 3-[18F]Fluoro-para-hydroxyphenethylguanidine ([18F]3F-PHPG) in Patients With Neuroendocrine Tumors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
32
Start Date
2020-10-19
Completion Date
2024-12-31
Last Updated
2026-06-08
Healthy Volunteers
No
Conditions
Interventions
3-[18F]Fluoro-para-hydroxyphenethylguanidine
Single IV injection of 12.0 mCi (+/- 10%) \[18F\]3F-PHPG
[123I] metaiodobenzylguanidine
Single IV injection of 10.0 mCi \[123I\]MIBG
Positron emission tomography/computed tomography scan
Whole-body PET/CT scan performed at two time-points: 1.5 hours and 3 hours after IV injection of \[18F\]3F-PHPG
Planar scintigraphy scan
Whole-body scan using planar scintigraphy with a gamma camera performed the day after IV injection of \[123I\]MIBG
Single photon emission computed tomography/computed tomography scan
SPECT/CT scan of the primary neuroendocrine tumor performed the day after IV injection of \[123I\]MIBG
Locations (1)
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, United States